Davunetide
Also called NAP, AL-108, AL-208
Intranasal (in the nose)Human study reference
Research reference
Human study
Davunetide phase 2/3 PSP trial
30 mg by nasal spray twice daily
52 weeks
Boxer et al., Lancet Neurology (2014) ↗When results may show
- When change was measured
- The primary PSP and daily-living outcomes did not improve versus placebo at 52 weeks.
- When to assess
- 52 weeks
- Conditions and limitations
- 313 adults with progressive supranuclear palsy. A negative condition-specific trial is not an effective cognitive-enhancement protocol. The nasal study formulation cannot define injected-vial dosing.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Modelled level — twice a day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 5hours
- Administrations
- 14/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Boxer et al., Lancet Neurology (2014)A negative condition-specific trial is not an effective cognitive-enhancement protocol. The nasal study formulation cannot define injected-vial dosing.